Promotions & Moves

FUJIFILM Diosynth Biotechnologies Appoints CEO

Martin Meeson succeeds Steve Bagshaw, who has decided to retire, effective April 1

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Steve Bagshaw, chief executive officer of FUJIFILM Diosynth Biotechnologies (FDB), has decided to retire from his current position, effective April 1, 2020. He will continue with the company in the role of non-executive Chairman and will assist with the transition in executive leadership.   Martin Meeson has been appointed to succeed Steve Bagshaw as chief executive officer. Mr. Meeson currently serves as president and chief operating officer of FUJIFILM Diosynth Biotechnologies, U.S.A., Inc. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters